Edition:
United Kingdom

Adocia Announces Positive Topline Results For First Clinical Study Of ADO09


Tuesday, 9 Apr 2019 

April 9 (Reuters) - ADOCIA SA ::ADOCIA ANNOUNCES POSITIVE TOPLINE RESULTS FOR THE FIRST CLINICAL STUDY OF ADO09, A NEW CO-FORMULATION OF PRAMLINTIDE AND A PRANDIAL INSULIN ANALOG, IN PEOPLE WITH TYPE 1 DIABETES.ADO09 IS FIRST CO-FORMULATION OF PRAMLINTIDE AND RAPID-ACTING A21G HUMAN INSULIN ANALOG, METABOLITE OF INSULIN GLARGINE.ADO09 SHOWED A SIGNIFICANT 85% DECREASE IN BLOOD GLUCOSE EXCURSION OVER FIRST TWO HOURS AFTER A MEAL COMPARED TO HUMALOG.ADO09 SHOWED SIMILAR GLUCOSE CONTROL OVER FIRST TWO HOURS AFTER A MEAL COMPARED TO SEPARATE INJECTIONS OF SYMLIN AND HUMULIN.ALL TREATMENTS WERE WELL TOLERATED.WE WILL NOW MOVE QUICKLY INTO A PHASE 2 CLINICAL TRIAL.".EXPECTS TO LAUNCH A PHASE 1/2, OUTPATIENT, 3-WEEK TRIAL OF ADO09 DURING THIS QUARTER. 

Related Company News

Company Quote

11.42
0.12 +1.06%
13 Sep 2019